Hosted on MSN1mon
Mersana falls after early-stage trial data for lead cancer therapyCancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results from a Phase 1 trial for its lead candidate emiltatug ledadotin (Emi-Le ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback